Takeda Pharmaceutical Company Limited

Dyax Corporation

Magenta Therapeutics, Inc.

Athera Biotechnologies Ab

Andrew Nixon

Daniel J Sexton

Burt Adelman

Jon A Kenniston

Gregory P Conley

Stephen R Comeau

Shauna Mason

Ryan Faucette

Christopher TenHoor

Robert Charles Ladner

Anthony Williams

Knut Pettersson

Dwight Morrow

Adam Hartigan

Ola Camber

Allison P Lindberg

Niksa Kastrapeli

Kristopher Kopacz

Dan Sexton

Qi-Long Wu

Christopher Tenhoor

Edwin L Madison

Yung Chyung

Greg Conley

Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.

Assays for determining plasma kallikrein system biomarkers

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Monoclonal antibody inhibitor of Factor XIIa

Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.

Bispecific antibodies against plasma kallikrein and factor XII

Disclosed herein are antibodies capable of binding to plasma kallikrein and inhibit its activity. Such antibodies interact with one or more critical residues in the catalytic domain of the plasma kallikrein. The antibodies may also contain specific heavy chain complementarity determining region 3 (CDRs) motifs and optionally specific residues at certain positions within both the heavy chain variable region and the light chain variable region.

Anti-plasma kallikrein antibodies

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

Compositions and methods for treatment of diabetic macular edema

Methods, kits and compositions for diagnosing and treating autoimmune diseases such as rheumatiodi arthritis. Crohn's disease, and ulcerative colitis.

Diagnosis and treatment of autoimmune diseases

Bispecific antibodies against plasma kallikrein and Factor XII

The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.

Methods of determining levels of cleaved and/or intact kininogen

Monoclonal antibody inhibitor of factor XIIA

Methods, kits and compositions for diagnosing and treating autoimmue diseases such as rheumatiodi arthritis, Crohn's disease, and ulcerative colitis.

The invention provides compositions and methods useful for the depletion of cells, such as CD45+, CD135+, CD34+, CD90+, and/or CD110+ cells, and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, ligands, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD45+, CD135+, CD34+, CD90+, or CD110+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Methods for the depletion of cells

Growing community of inventors

Hanover, MA, United States of America

Andrew Nixon